Literature DB >> 17404272

Interdependency of MHC class II/self-peptide and CD1d/self-glycolipid presentation by TNF-matured dendritic cells for protection from autoimmunity.

Carsten Wiethe1, Matthias Schiemann, Dirk Busch, Lothar Haeberle, Manfred Kopf, Gerold Schuler, Manfred B Lutz.   

Abstract

Dendritic cells (DC) are key regulators of T cell immunity and tolerance. NKT cells are well-known enhancers of Th differentiation and regulatory T cell function. However, the nature of the DC directing T and NKT cell activation and polarization as well as the role of the respective CD1d Ags presented is still unclear. In this study, we show that peptide-specific CD4(+)IL-10(+) T cell-mediated full experimental autoimmune encephalomyelitis (EAE) protection by TNF-treated semimatured DCs was dependent on NKT cells recognizing an endogenous CD1d ligand. NKT cell activation by TNF-matured DCs induced high serum levels of IL-4 and IL-13 which are absent in NKT cell-deficient mice, whereas LPS plus anti-CD40-treated fully mature DCs induce serum IFN-gamma. In the absence of IL-4Ralpha chain signaling or NKT cells, no complete EAE protection was achieved by TNF-DCs, whereas transfer of NKT cells into Jalpha281(-/-) mice restored it. However, activation of NKT cells alone was not sufficient for EAE protection and early serum Th2 deviation. Simultaneous activation of NKT cells and CD4(+) T cells by the same DC was required for EAE protection. Blocking experiments demonstrated that NKT cells recognize an endogenous glycolipid presented on CD1d on the injected DC. Together, this indicates that concomitant and interdependent presentation of MHC II/self-peptide and CD1d/self-isoglobotrihexosylceramide to T and NKT cells by the same partially or fully matured DC determines protective and nonprotective immune responses in EAE.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17404272     DOI: 10.4049/jimmunol.178.8.4908

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  8 in total

Review 1.  The split personality of NKT cells in malignancy, autoimmune and allergic disorders.

Authors:  Jeff J Subleski; Qun Jiang; Jonathan M Weiss; Robert H Wiltrout
Journal:  Immunotherapy       Date:  2011-10       Impact factor: 4.196

2.  B7-H1-deficiency enhances the potential of tolerogenic dendritic cells by activating CD1d-restricted type II NKT cells.

Authors:  Carolin Brandl; Sonja Ortler; Thomas Herrmann; Susanna Cardell; Manfred B Lutz; Heinz Wiendl
Journal:  PLoS One       Date:  2010-05-24       Impact factor: 3.240

3.  Dendritic cell based genetic immunization stimulates potent tumor protection dependent on CD8 CTL cells in the absence of autoimmunity.

Authors:  Sheng Zhang; Weiyi Huang
Journal:  J Cancer Res Clin Oncol       Date:  2008-02-26       Impact factor: 4.553

4.  STAT3 promotes CD1d-mediated lipid antigen presentation by regulating a critical gene in glycosphingolipid biosynthesis.

Authors:  Abhirami K Iyer; Jianyun Liu; Richard M Gallo; Mark H Kaplan; Randy R Brutkiewicz
Journal:  Immunology       Date:  2015-09-21       Impact factor: 7.397

5.  Therapeutic potential of semi-mature dendritic cells for tolerance induction.

Authors:  Manfred B Lutz
Journal:  Front Immunol       Date:  2012-05-18       Impact factor: 7.561

6.  Role of dendritic cell maturity/costimulation for generation, homeostasis, and suppressive activity of regulatory T cells.

Authors:  Katrien Pletinckx; Anja Döhler; Vladimir Pavlovic; Manfred B Lutz
Journal:  Front Immunol       Date:  2011-09-27       Impact factor: 7.561

7.  The 30-kDa and 38-kDa antigens from Mycobacterium tuberculosis induce partial maturation of human dendritic cells shifting CD4(+) T cell responses towards IL-4 production.

Authors:  Marion Heuer; Anna-Sophie Behlich; Ji-Sook Lee; Eliana Ribechini; Eun-Kyeong Jo; Manfred B Lutz
Journal:  BMC Immunol       Date:  2013-10-03       Impact factor: 3.615

Review 8.  GM-CSF Monocyte-Derived Cells and Langerhans Cells As Part of the Dendritic Cell Family.

Authors:  Manfred B Lutz; Herbert Strobl; Gerold Schuler; Nikolaus Romani
Journal:  Front Immunol       Date:  2017-10-23       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.